Purpose This investigation aimed to identify significant predictors of regional sympathetic denervation quantified by 11 Chydroxyephedrine (HED) positron emission tomography (PET) in patients with heart failure with preserved left ventricular ejection fraction (HFpEF). Methods Included in the study were 34 patients (age 63 ± 15 years, 23 men) with HFpEF (left ventricular ejection fraction ≥40%) and 11 age-matched volunteers without heart failure. Cardiac magnetic resonance imaging was performed to measure left ventricular size and function, and the extent of myocardial late gadolinium enhancement (LGE).
Introduction
Myocardial sympathetic denervation has been recognized as an indicator of a poor prognosis in patients with heart failure [1, 2] . Regional sympathetic denervation in particular has been found to be a significant predictor of sudden cardiac death in patients with ischemic cardiomyopathy independent of infarct size [3] . An animal study using a porcine infarction model showed a stepwise decrease in myocardial sympathetic innervation and systolic wall thickening from normal to adjacent and from adjacent to infarcted myocardium [4] . Regional denervated myocardium has also been observed in patients with idiopathic dilated cardiomyopathy [5] [6] [7] and hypertrophic cardiomyopathy [8] [9] [10] . These findings suggest that regional sympathetic denervation may reflect functional and pathological alterations in both ischemic and nonischemic cardiomyopathy. Most previous studies have focused on myocardial sympathetic denervation in patients with heart failure with left ventricular (LV) ejection fraction <40% [1] [2] [3] [5] [6] [7] , while the implications of regional sympathetic denervation in those with LV ejection fraction ≥40%, which has been termed heart failure with preserved ejection fraction (HFpEF), have not been well investigated.
HFpEF is a common form of heart failure and is functionally characterized by diastolic dysfunction accompanying myocardial fibrosis [11, 12] . Recently, we demonstrated that myocardial sympathetic denervation, as measured by 11 Chydroxyephedrine ( 11 C-HED) positron emission tomography (PET), in patients with HFpEF is related to the severity of diastolic dysfunction independently of LV ejection fraction [13] . A detailed understanding of the regional sympathetic denervation in patients with HFpEF may be useful for risk stratification or monitoring because myocardial sympathetic denervation may reflect the pathophysiological process in HFpEF. Cardiac magnetic resonance (CMR) imaging allows noninvasive assessment of contractile function and fibrotic changes in various cardiomyopathies [14] [15] [16] . Thus, we aimed to identify the predictors of regional sympathetic denervation in patients with HFpEF by functional and morphological tissue characterization using 11 C-HED PET and CMR imaging.
Materials and methods

Study population
We studied 34 patients with HFpEF at Hokkaido University Hospital between November 2012 and November 2015. HFpEF was diagnosed when all of the following criteria were met: chronic congestive heart failure, diagnosis based on the Framingham Heart Study criteria [17] , presence of LVejection fraction ≥40%, based on two-dimensional echocardiography; and a history of hospital admission for cardiac reasons. HFpEF patients were divided into those with coronary artery disease (CAD, 11 patients) and those without CAD (non-CAD, 23 patients), with CAD defined as ≥70% narrowing of a major epicardial coronary artery detected by invasive coronary angiography, a history of myocardial infarction; or evidence of ischemia or infarction detected by stress myocardial perfusion imaging [18] . All participants were recruited as part of a previous study [13] . Exclusion criteria were severe left-sided valvular heart disease on echocardiography, contraindications to CMR imaging (such as metallic implants and claustrophobia), and estimated glomerular filtration rate <30 mL min −1 1.73 m −2 . Also included were 11 agematched control participants with normal LV ejection fraction without valvular heart disease and no cardiovascular disease. All participants underwent CMR imaging and 11 C-HED PET within 1 month of each other (median interval 3 days, interquartile range 0-7 days), and no clinical events occurred between the two examinations. All patients were prospectively followed up by their physician, or via telephone interview, to assess adverse events, including acute decompensated heart failure requiring hospitalization, life-threatening ventricular arrhythmias, and all-cause death. The study was approved by the Ethics Committee of Hokkaido University Hospital (IRB 012-0098) and was registered with the University Hospital Medical Information Network clinical trials registry (UMIN000009386). All participants provided written informed consent.
CMR imaging protocol
CMR imaging was performed using a 1.5-T whole-body scanner (Achieva; Philips Medical Systems, Best, The Netherlands) with a five-channel phased-array cardiac coil (13 patients) or a 3-T whole-body scanner (Achieva TX, Philips Medical Systems) with a 32-channel phased-array receiver torsocardiac coil (32 patients) in accordance with standardized CMR protocols [19] , as described elsewhere [20] [21] [22] . In brief, after localization of the heart, a series of LV short-axis cine images from base to apex were obtained using a retrospectively electrocardiogram-gated, balanced steady-state free precession pulse sequence during repeated breath-holds. Late gadolinium enhancement (LGE) images at matching cine-image slice locations were obtained 10-15 min after administration of 0.1 mmol/kg of Gd-DTPA using an inversion-recovery prepared, three-dimensional fast field echo pulse sequence.
CMR image analysis
CMR image analysis was performed using commercially available software (Ziostation2; Ziosoft Inc., Tokyo, Japan). LV volumes, ejection fraction, mass, and wall thickness were measured by semiautomatically outlining the endocardial and epicardial borders of the myocardium on the short-axis cine images. Regional systolic wall thickening was calculated as follows: ([end-diastolic wall thickness − end-systolic wall thickness]/end-diastolic wall thickness) × 100%. The extent of hyperenhanced myocardium on LGE images was quantified as the percentage area of hyperenhanced myocardium using a threshold of five standard deviations above the mean of remote myocardium [22, 23] . The LV myocardium was automatically divided into 16 segments of the American Heart Association 17-segment model, excluding the apex segment.
11
C-HED PET protocol 11 C-HED PET was performed using a whole-body PET/CT scanner (Biograph 64 TruePoint; Siemens Japan, Tokyo, Japan). Participants were instructed to fast for at least 4 h prior to the scan, and to avoid substances containing caffeine or methylxanthine for at least 24 h prior to the scan.
C-HED PET scanning was performed as described previously [13] . In brief, after a low-dose CT scan for attenuation and scatter correction, a bolus of 185 MBq of 11 C-HED was injected simultaneously with the start of a 40-min list-mode acquisition. PET images were reconstructed into 21 frames (9 × 10 s, 3 × 30 s, 2 × 60 s, and 7 × 300 s) using filtered back-projection with 10-mm full-width at half-maximum Gaussian postsmoothing, a matrix size of 128 × 128, and a voxel size of 3.6 × 3.6 × 2.0 mm.
PET image analysis
PET images were analyzed using software developed inhouse. Short-axis images in the last frame of the dynamic scan were used to define a region of interest in the LV, which was semiautomatically divided into the 17 segments based on the American Heart Association recommendation. Image-derived input functions were obtained from a region of interest manually placed at the basal LV cavity of the valve plane. A 11 C-HED retention index (RI, %/min) as a measure of myocardial sympathetic innervation was calculated as the mean myocardial activity in the last frame (30 to 40 min) divided by the integral of the arterial input function [5, 7, 13] . The coefficient of variation of the regional 11 C-HED RI among the 17 segments (CVRI) was also calculated as a measure of heterogeneity in myocardial 11 C-HED uptake [13] . A segment was considered to have a denervation-scar mismatch if the segment had no LGE (<1% of the segment) and regional 11 C-HED RI below the 25th percentile of the control group range (<8.3%/min). The mismatch size was expressed as percent LV.
Statistical analysis
All statistical analyses were performed using JMP Pro 12.0.1 (SAS Institute Inc., Cary, NC). Continuous variables are presented as medians and interquartile ranges. Categorical variables are presented as absolute numbers and percentages. The significance of differences between groups were evaluated using the Kruskal-Wallis test followed by the Steel-Dwass test for multiple comparisons. Correlations between two variables were evaluated by linear regression analysis. LV ejection fraction measurements obtained using two-dimensional echocardiography and by volumetric CMR imaging were compared using the Wilcoxon signed-ranks test. To assess the interactions among regional sympathetic denervation, systolic wall thickening, the extent of LGE, and LV end-diastolic wall thickness in patients with HFpEF on a per-segment basis, a multivariate analysis was performed using a mixed-effects model for repeated measures of the 16 segments per-patient, adjusting for age, sex, body mass index, past medical history (hypertension, diabetes, hyperlipidemia, and atrial fibrillation), the presence of CAD, β-blocker use, and intermediate LV ejection fraction (<50% based on CMR images). An unstructured covariance matrix was used to account for correlation between segments. A two-tailed P value of less than 0.05 was considered statistically significant.
Results
Clinical characteristics
The clinical characteristics of participants are shown in Table 1 . The non-CAD group included patients with diagnoses of hypertrophic cardiomyopathy (seven patients), hypertensive heart disease (four patients), idiopathic dilated cardiomyopathy (four patients), cardiac sarcoidosis (four patients), cardiac amyloidosis (two patients), tachycardia-induced cardiomyopathy (one patient), and prior myocarditis (one patient). There was no significant difference in age between the control and HFpEF groups, although the CAD group was more likely to be male and more frequently treated with a statin and an antiplatelet agent. The majority of patients in the two HFpEF groups (88%) had symptomatic heart failure (New York Heart Association class II/III). The levels of plasma B-type natriuretic peptide in the two HFpEF groups were significantly higher than in the control group (P < 0.05 for both).
Per-participant analysis
Representative images are shown in Fig. 1 . Table 2 summarizes the PET and CMR imaging results. Overall, the two HFpEF groups had significantly larger LV volumes and masses, and a lower LV ejection fraction than the control group (P < 0.05 for all). Although there were differences in the LV measurements obtained using echocardiography and CMR imaging, the LVejection fractions obtained with the two modalities showed a good correlation (r = 0.90, P < 0.001), without significant differences (mean difference 1.2%, 95% confidence interval −1.0% to 3.5%; P = 0.38). No participant in the control group had hyperenhanced myocardium on LGE images. Two patients with cardiac amyloidosis were excluded from further analysis because they showed diffuse hyperenhancement on LGE images, the extent of which could not be measured. LV volume, mass, and the extent of LGE did not significantly differ between the two HFpEF groups. In the non-CAD group, patients with hypertrophic cardiomyopathy tended to have a higher LV mass (138.8 g, interquartile range 114.1 to 212.5 g) compared to those without (120.5 g, interquartile range 93.9 to 135.6 g). However, this difference was not statistically significant (P = 0.10). Regarding the PET imaging results, the two HFpEF groups showed significantly lower global 11 C-HED RI and larger CVRI than the control group (P < 0.01 for all), whereas the global 11 C-HED RI, CVRI, and denervation-scar mismatch size were not significantly different between the two HFpEF groups (P = 0.51 and P = 0.96, respectively). On a participant basis, LV ejection fraction, volume, mass, and the extent of LGE were significantly correlated with global 11 C-HED RI and CVRI (P < 0.05 for all; Table 3 ). The denervation-scar mismatch size was not significantly correlated with LV ejection fraction, volume, or mass.
Per-segment analysis HFpEF heart failure with preserved ejection fraction, CAD coronary artery disease, NYHA New York Heart Association, ACE-I angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker a P < 0.01 vs. control Segments with a large extent of LGE (>10% of the segment) in the HFpEF groups had the lowest 11 C-HED RI among all segments of the population (P < 0.001 in post hoc tests). The data showed a modest stepwise decrease in regional 11 C-HED RI with decreasing systolic wall thickening and increasing extent of LGE. The regional 11 C-HED RIs in segments with a small extent of LGE (1% to 10% of the segment) were comparable to those in segments with decreasing systolic wall thickening (<75%) and no LGE (P = 1.00). HFpEF heart failure with preserved ejection fraction, CAD coronary artery disease, LV left ventricular, LGE late gadolinium enhancement, RI retention index, CVRI coefficient of variation of regional retention index among the 17 segments a P < 0.01 vs. control b P < 0.05 vs. control.
c Excluding the two patients with cardiac amyloidosis
Predictors of regional sympathetic denervation in cardiomyopathy Table 4 shows the results of the mixed-effects model exploring the interactions among regional 11 C-HED RI, CMR imaging variables, and baseline characteristics in the two HFpEF groups on a per-segment basis. Systolic wall thickening, the extent of LGE, and LV end-diastolic wall thickness were independently associated with regional 11 C-HED RI (P ≤ 0.001 for all), whereas baseline characteristics, the presence of CAD, and intermediate LV ejection fraction (< 50%) were not significantly associated with regional 11 C-HED RI. C-HED RI (<10%/min; the lower quartile value of the control group segments) was found in 76% of all segments in 32 patients with HFpEF (excluding two patients with cardiac amyloidosis). The majority of segments with impaired regional 11 C-HED RI had decreased systolic wall thickening and the presence of LGE. Numbers in parentheses are numbers of segments C-HED retention index (RI) and systolic wall thickening (a), the extent of myocardial late gadolinium enhancement (LGE) (b), and left ventricular end-diastolic wall thickness (c) on a per-segment basis (HFpEF heart failure with preserved ejection fraction, CAD coronary artery disease, CI confidence interval) 
Clinical follow-up
During the follow-up period (median 21 months, range 17 to 36 months) no patient died and appropriate implantable cardioverter-defibrillator discharge occurred in only one patient in whom low global 11 C-HED RI (7.4%/min) and a large CVRI (17.7%) were observed. Two patients were admitted for acute decompensated heart failure. The low event rate in the present study precluded meaningful interpretation of 11 C-HED PET variables.
Discussion
This study showed that myocardial sympathetic innervation in patients with HFpEF was more reduced and more heterogeneous than in control participants. Denervation-scar mismatch was found in patients without CAD as well as in those with CAD. On a per-segment basis, systolic wall thickening, the extent of LGE, and LV end-diastolic wall thickness were significant predictors of regional sympathetic denervation in patients with HFpEF, suggesting that regional sympathetic denervation may provide an integrated measure of myocardial damage in HFpEF.
Heterogeneous reductions in myocardial sympathetic innervation in various cardiomyopathies are in line with the results of previous studies [3, 5, [7] [8] [9] [10] . Myocardial sympathetic denervation in CAD is observed in the infarct core and the surrounding border zone [3, 4, 24] . In contrast, denervated myocardium is located in the apex and inferior wall in patients with idiopathic dilated cardiomyopathy [5, 7] and in the hypertrophic wall in patients with hypertrophic cardiomyopathy [8] , indicating that a heterogeneous reduction may not be directly associated with myocardial ischemia in the failing heart.
On a per-segment basis, regional decreases in myocardial sympathetic innervation were found not only in the segments with scarring but also in those without scarring with contractile dysfunction. Furthermore, systolic wall thickening and the extent of myocardial scarring were independently associated with regional sympathetic denervation in patients with HFpEF. These observations suggest that the autonomic nervous system is involved in the early pathophysiological changes in HFpEF. A previous study in patients with idiopathic dilated cardiomyopathy showed a significant correlation between regional 11 C-HED RI and systolic wall thickening [5] . Although regional sympathetic denervation in patients with HFpEF is expected to correlate with contractile dysfunction or myocardial scarring, such data are so far lacking. To our knowledge, this is the first study demonstrating a quantitative association between regional sympathetic denervation, contractile dysfunction, and myocardial scarring in HFpEF due to various cardiomyopathies.
In contrast with a previous report in patients with hypertrophic cardiomyopathy [8] , increases in LV wall thickness were associated with increases in regional sympathetic innervation in the multivariate analysis. A possible reason for this difference is the partial volume effect of 11 C-HED, which can lead to overestimation of myocardial sympathetic innervation. To mitigate this, we included LV end-diastolic wall thickness in the multivariate mixed-effects model. In patients with hypertrophic cardiomyopathy, the hypertrophied region, typically in the interventricular septum, often shows myocardial fibrosis (detected as LGE), which correlates with decreasing systolic wall thickening [16] . Therefore, both myocardial fibrosis and contractile dysfunction may affect regional sympathetic denervation in the hypertrophied region in patients with hypertrophic cardiomyopathy.
We focused on regional decreases in myocardial 11 C-HED uptake because the quantification of regional sympathetic denervation as a predictor of ventricular arrhythmias has been reported in clinical practice [3, 25] . Ischemic myocardium, which can be assessed by myocardial perfusion and metabolic imaging, is recognized as the most common cause of ventricular arrhythmias [26] . The extent of the denervated myocardium exceeds the area of infarction and indicates the ischemic area at risk [27] , suggesting that they may assess a similar arrhythmogenic substrate. These findings, as well as our results, highlight the high sensitivity of sympathetic innervation to various forms of myocardial damage.
Myocardial fibrosis is one of the significant substrates for ventricular arrhythmias. CMR imaging allows noninvasive assessment of myocardial fibrosis. The presence and extent of LGE have been reported to predict adverse arrhythmic events LGE late gadolinium enhancement in patients with cardiomyopathy [18] . Global and regional alterations in myocardial sympathetic innervation have also been described as a possible predictor of ventricular tachyarrhythmia [3, 25, 28, 29] . Recently, the Prediction of ARrhythmic Events with Positron Emission Tomography study of 204 patients with ischemic cardiomyopathy (mean LVEF 27 ± 9%) demonstrated that infarct size and LVejection fraction were not independent predictors of sudden cardiac death, but the extent of regional sympathetic denervation quantified using 11 C-HED PET was an independent predictor [3] . In contrast to CMR imaging, cardiac sympathetic imaging can be used in patients with an implantable device. Although the primary focus of this study was the cross-sectional comparison between regional sympathetic denervation and other variables, further research is required to clarify the clinical value of assessing regional sympathetic denervation in HFpEF.
The current study had several limitations. First, we did not perform stress myocardial perfusion imaging in the study participants. Myocardial perfusion may affect sympathetic innervation. However, perfusion imaging is not necessarily required for the clinical assessment of HFpEF. Second, we did not evaluate the pattern of regional sympathetic denervation in patients with specific cardiomyopathies. However, multivariate analysis demonstrated the association between regional sympathetic denervation, contractile dysfunction, and myocardial scarring independent of CAD. Third, this crosssectional study could not conclusively determine the causeeffect association between regional sympathetic denervation and other variables. Whether sympathetic denervation primarily causes myocardial damage remains unclear.
Conclusion
The present study demonstrated that regional sympathetic denervation is associated with contractile dysfunction and the extent of myocardial scarring in patients with HFpEF, suggesting that regional sympathetic denervation may provide an integrated measure of myocardial damage in HFpEF. Further research is needed to assess the prognostic value of regional sympathetic denervation in HFpEF.
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